Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Tarsus Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.84 | -$0.76 | -$0.81 |
| Q2 2025 | 1 | -$0.54 | -$0.44 | -$0.48 |
| Q3 2025 | 1 | -$0.43 | -$0.35 | -$0.39 |
| Q4 2025 | 1 | -$0.15 | -$0.12 | -$0.14 |
| Q1 2026 | 1 | -$0.03 | -$0.03 | -$0.03 |
| Q2 2026 | 1 | $0.17 | $0.21 | $0.19 |
| Q3 2026 | 1 | $0.30 | $0.37 | $0.33 |
| Q4 2026 | 1 | $0.43 | $0.53 | $0.47 |
Tarsus Pharmaceuticals, Inc. Earnings Date And Information
Tarsus Pharmaceuticals, Inc. last posted its earnings results on Tuesday, February 25th, 2025. The company reported $-0.6 earnings per share for the quarter, topping analysts' consensus estimates of $-0.68 by $0.08. The company had revenue of 66.41 M for the quarter and had revenue of 182.95 M for the year. Tarsus Pharmaceuticals, Inc. has generated $-3 earnings per share over the last year ($-3.07 diluted earnings per share) and currently has a price-to-earnings ratio of -15.65. Tarsus Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based on prior year's report dates.
Tarsus Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/25/2025 | Q4 2024 | -$0.68 | -$0.61 | 0.07 | $58.80 M | $66.41 M |
| 11/13/2024 | Q3 2024 | -$0.94 | -$0.61 | 0.33 | $43.18 M | $48.12 M |
| 08/08/2024 | Q2 2024 | -$0.98 | -$0.88 | 0.1 | $32.33 M | $40.81 M |
| 05/08/2024 | Q1 2024 | -$1.15 | -$1.01 | 0.14 | N/A | $27.61 M |
| 02/27/2024 | Q4 2023 | -$1.37 | -$1.31 | 0.06 | $5.47 M | $13.08 M |
| 11/09/2023 | Q3 2023 | -$1.40 | -$1.28 | 0.12 | $399,560 | $1.87 M |
| 08/10/2023 | Q2 2023 | -$1.08 | -$1.17 | -0.09 | N/A | $15.28 M |
| 05/09/2023 | Q1 2023 | -$0.95 | -$0.82 | 0.13 | N/A | $2.50 M |
| 03/16/2023 | Q4 2022 | N/A | -$0.49 | N/A | N/A | $10.00 M |
| 11/09/2022 | Q3 2022 | -$0.98 | -$0.84 | 0.14 | $3.50 M | $0 |
| 08/11/2022 | Q2 2022 | -$0.65 | -$0.26 | 0.39 | $11.25 M | $15.28 M |
| 05/11/2022 | Q1 2022 | N/A | -$0.98 | N/A | N/A | $539,000 |
| 03/14/2022 | Q4 2021 | -$0.77 | -$0.72 | 0.05 | N/A | $338,000 |
| 11/10/2021 | Q3 2021 | N/A | -$0.76 | N/A | $5.33 M | $1.24 M |
| 08/04/2021 | Q2 2021 | N/A | $0.31 | N/A | $4.53 M | $22.02 M |
| 05/11/2021 | Q1 2021 | -$0.64 | $0.51 | 1.15 | N/A | $33.43 M |
| 03/31/2021 | Q4 2020 | -$0.66 | -$0.56 | 0.1 | N/A | $0 |
| 11/24/2020 | Q3 2020 | N/A | -$0.54 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$0.30 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.18 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Tarsus Pharmaceuticals, Inc. Earnings: FAQ's
Tarsus Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based offlast year's report dates.
In the previous quarter, Tarsus Pharmaceuticals, Inc. (:TARS) reported $-0.6 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.68 by $0.08.
The conference call for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Tarsus Pharmaceuticals, Inc.'s latest earnings report can be read online.
Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded annual revenue of $182.95 M.
Tarsus Pharmaceuticals, Inc. (:TARS) has a recorded net income of $-115,554,000.Tarsus Pharmaceuticals, Inc. has generated $-3.07 earnings per share over the last four quarters.
Tarsus Pharmaceuticals, Inc. (:TARS) has a price-to-earnings ratio of -15.65 and price/earnings-to-growth ratio is -0.85.